Terapia Genica e Cellulare

Laboratori 2024/2025 - Terapia Genica e Cellulare

Di seguito è possibile visionare l’elenco dei Supervisori (e i link ai rispettivi CV) e i progetti presentati per l' a.a. 2024/2025 all'interno del curriculum in Terapia Genica e Celllulare.

Nell'elenco sono riportate le borse a progetto e a seguire i progetti liberi tra cui i candidati, risultati idonei alla seconda fase di valutazione, dovranno scegliere i progetti di preferenza così come indicato nel bando.

9 BORSE A PROGETTO:

BORSA A PROGETTO GCT1: ANNONI ANDREA

Unit: Immune Core Unit– IRCCS Ospedale San Raffaele

GCT1: Engineering Thymic Selection to Control the Development of Alloreactive T Cells to promote acceptance of allogeneic transplantation

BORSA A PROGETTO GCT2: APRILE ANNAMARIA

Unit: Gene transfer into stem cells Unit, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) – IRCCS Ospedale San Raffaele

GCT2: Targeting the hematopoietic stem cell niche to improve gene therapy for hemoglobinopathies

BORSA A PROGETTO GCT3: CANTORE ALESSIO

Unit: Liver gene therapy – The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) – IRCCS Ospedale San Raffaele

GCT3: Dissecting hepatocyte heterogeneity in liver growth to improve in vivo gene therapy

BORSA A PROGETTO GCT4: CESANA DANIELA

Unit: San Raffaele Telethon Institute for Gene Therapy, Safety of Gene therapy and insertional mutagenesis Unit – IRCCS Ospedale San Raffaele

GCT4: cell-free DNA as an early molecular response biomarker of CAR-T cell activity and efficacy

BORSA A PROGETTO GCT5: DITADI ANDREA

Unit: Human hematopoietic development and disease modeling Unit – IRCCS Ospedale San Raffaele

GCT5: Gene expression dynamics of blood cell emegence

BORSA A PROGETTO GCT6: OSTUNI RENATO

Unit: Genomics of the innate immune system Unit– IRCCS Ospedale San Raffaele

GCT6: Epigenetic regulators of inflammatory responses

BORSA A PROGETTO GCT7: CASUCCI MONICA

Unit: Immunoterapie Innovative – IRCCS Ospedale San Raffaele

GCT7: Optimizing the therapeutic index of CD44v6 CAR T cells

BORSA A PROGETTO GCT8: CRIPPA STEFANIA

Unit: Pathogenesis and therapy of primary immunodeficiencies Unit Telethon Institute for Gene Therapy– IRCCS Ospedale San Raffaele

Finanziata dall’Unione Europea – NextGeneration EU - ai sensi del DM 630/2024

GCT8: Pre-clinical development of HSPC-GT for Morquio syndrome

BORSA A PROGETTO GCT9: BONINI CHIARA

Unit: Experimental Hematology Unit – IRCCS Ospedale San Raffaele

Finanziata dall’Unione Europea – NextGeneration EU - ai sensi del DM 630/2024.

GCT9: Uncover and overcome senescence and dysfunction of genetically engineered T lymphocytes for cancer immunotherapy

BALESTRIERI CHIARA

Unit: Experimental Hematology Unit e Center for Omics Sciences

Unraveling Mechanisms and Targeting Liver Metastasis in Pancreatic Cancer: Insights into the Metastatic Microenvironment

BROCCOLI VANIA

Unit: Cellule Staminali e Neurogenesi, Divisione di Neuroscienze

Isolating and validating new engineered AAV vectors for efficient brain transduction and efficacious gene therapy in a Rett disease mouse model

COLASANTE GAIA

Unit: Cellule Staminali e Neurogenesi

Investigating and enhancing the trafficking of Nav1.1 channel to set a gene therapy for Dravet Syndrome

COLTELLA NADIA

Unit: Targeted cancer Gene Therapy Unit 

Targeted delivery of orthogonal cytokines to safely improve CAR-T function within the tumor microenvironment of solid tumors

DI MICCO RAFFAELLA

Unit: SR-TIGET Group Leader, Senescence in Stem Cell Aging, Differentiation and Cancer

Studying the inetrplay between senescent cancer cells and the immune micronvironment in acute myeloid leukemia

FERRARI SAMUELE

Unit: Gene transfer technologies and new gene therapy strategies

Addressing the Unknowns of VEXAS syndrome by Single-cell Multiomic Clonal Tracking and Targeted Genome Editing

OMER ATTYA

Unit: Gene transfer technologies and new gene therapy strategies

Mobilization and Antibody-Mediated Conditioning: A Dual Approach to Maximize Chemotherapy-free Hematopoietic Stem Cell Therapy

SQUADRITO MARIO LEONARDO

Unit: Targeted cancer gene therapy

In vivo genetic engineering of liver metastases to modulate immune circuits